Shots:
- The P-III CheckMate-816 study involves assessing Opdivo (360mg) + CT (q3w for 3 doses) vs CT, followed by surgery as a neoadjuvant treatment in 358 patients with resectable stage Ib to IIIa NSCLC
- The study met its 1EPs, i.e. improvement in pCR (24% vs 2.2%) and showed improvement in 2EPs i.e. MPR (36.9% vs 8.9), patients who underwent surgery showed that Opdivo did not decrease the feasibility of performing surgery (83% vs 75%), patients whose tumors were R0 (83% vs 78%)
- Opdivo-based treatments showed benefits in 4 P-III clinical trials in early-stage cancers, including lung cancer, bladder cancer, esophageal/GEJ cancer and melanoma
Click here to read full press release/ article | Ref: Businesswire | Image: Fierce Pharma
The post BMS Presents Results of Opdivo (nivolumab) + CT in P-III CheckMate-816 Trial for Resectable NSCLC at AACR2021 first appeared on PharmaShots.
